Drug Trial Radar · NCT05070195
A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Oct 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Jun 7, 2021
Primary completion
Jul 9, 2021
Study completion Jul 9, 2021
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, open-label phase I clinical study to investigate the effect of SKLB1028 on the pharmacokinetics of Midazolam and its metabolite 1'-OH-midazolam in healthy subjects. This study also aims to evaluate the safety and tolerability of SKLB1028 in the presence of Midazolam.
Conditions
- Healthy Subjects
Interventions
SKLB1028Drug
SKLB1028, capsule, oral
MidazolamDrug
Midazolam Maleate, tablet, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum concentration (Cmax)of Midazolam and its metabolite 1'-OH-midazolamTime frame: Day 1 and Day 3(0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hrs post-dose)
- Area under the concentration-time curve (AUC) from 0 to the last measurable concentration (AUC0-t) of Midazolam and its metabolite 1'-OH-midazolamTime frame: Day 1 and Day 3(0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hrs post-dose)
- AUC extrapolated to infinity (AUCinf) of Midazolam and its metabolite 1'-OH-midazolamTime frame: Day 1 and Day 3(0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hrs post-dose)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.